Jiangsu Aidea Pharmaceutical Future Growth

Future criteria checks 2/6

Jiangsu Aidea Pharmaceutical is forecast to grow revenue at 36.9% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	32.5%
Revenue growth rate	36.9%
Future return on equity	0.3%
Analyst coverage	Low
Last updated	07 Jun 2024

Recent future growth updates

No updates

Recent updates

Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Jun 07

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Mar 01

Earnings and Revenue Growth Forecasts

SHSE:688488 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,080	N/A	N/A	109	2
12/31/2025	835	N/A	N/A	-186	2
12/31/2024	509	N/A	N/A	1	2
3/31/2024	392	-90	-255	-180	N/A
12/31/2023	411	-76	-237	-166	N/A
9/30/2023	412	-80	-203	-115	N/A
6/30/2023	409	-66	-246	-146	N/A
3/31/2023	322	-101	-233	-123	N/A
12/31/2022	244	-124	-233	-93	N/A
9/30/2022	180	-114	-204	-69	N/A
6/30/2022	172	-111	-158	-31	N/A
3/31/2022	213	-64	-169	-41	N/A
12/31/2021	256	-30	-107	-12	N/A
9/30/2021	309	17	-129	-40	N/A
6/30/2021	317	28	-118	-31	N/A
3/31/2021	322	48	-9	44	N/A
12/31/2020	289	40	14	56	N/A
9/30/2020	327	51	16	41	N/A
6/30/2020	311	42	70	86	N/A
3/31/2020	309	31	70	90	N/A
12/31/2019	345	34	23	56	N/A
12/31/2018	277	9	-123	-33	N/A
12/31/2017	136	-38	N/A	-67	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 688488's forecast earnings growth is above the savings rate (2.9%).

Earnings vs Market: Insufficient data to determine if 688488's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 688488's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688488's revenue (36.9% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 688488's revenue (36.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688488's Return on Equity is forecast to be low in 3 years time (0.3%).

Jiangsu Aidea Pharmaceutical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Full year 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.30 loss in FY 2022)

Jiangsu Aidea Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Full year 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.30 loss in FY 2022)

Second quarter 2023 earnings released: CN¥0.018 loss per share (vs CN¥0.11 loss in 2Q 2022)

New major risk - Share price stability

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: CN¥0.29 loss per share (vs CN¥0.07 loss in FY 2021)

Full year 2022 earnings released: CN¥0.29 loss per share (vs CN¥0.07 loss in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.02 loss per share (vs CN¥0.045 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.11 loss per share (vs CN¥0.003 profit in 2Q 2021)

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) agreed to acquire 19.9646% stake in Nanjing Nanda Pharmaceutical Co., Ltd. from Jiangsu Sheng Feng Medical Technology Company Limited for CNY 86 million.

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.03 profit in 1Q 2021)

Full year 2021 earnings released: CN¥0.07 loss per share (vs CN¥0.10 profit in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: CN¥0.045 loss per share (vs CN¥0.014 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.053 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.01 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.09 in FY 2019)

New 90-day low: CN¥19.66

New 90-day low: CN¥19.86

New 90-day low: CN¥26.00

New 90-day low: CN¥26.80

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies